METHODS FOR DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS
First Claim
Patent Images
1. A method for facilitating the diagnosis of a patient for a cancer of epithelial origin comprising:
- a. obtaining a biological sample from the patient; and
b. detecting the presence or absence of at least one epithelial cancer biomarker in the biological sample, wherein the presence of at least one epithelial cancer biomarker is indicative of cancer of epithelial origin, and wherein the epithelial cancer biomarker is selected from the group consisting of Cystatin B, Chaperonin 10, and Profilin.
5 Assignments
0 Petitions
Accused Products
Abstract
The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy.
-
Citations
37 Claims
-
1. A method for facilitating the diagnosis of a patient for a cancer of epithelial origin comprising:
-
a. obtaining a biological sample from the patient; and
b. detecting the presence or absence of at least one epithelial cancer biomarker in the biological sample, wherein the presence of at least one epithelial cancer biomarker is indicative of cancer of epithelial origin, and wherein the epithelial cancer biomarker is selected from the group consisting of Cystatin B, Chaperonin 10, and Profilin. - View Dependent Claims (3, 7, 8, 9, 10, 11, 12)
-
-
2. A method for diagnosing a cancer of epithelial origin in a patient comprising:
-
a. measuring at least one epithelial cancer biomarker levels present in a biological sample obtained from the patient, a test sample;
b. comparing the level of at least one epithelial cancer biomarker in the test sample with the level of epithelial cancer biomarker present in a control sample;
wherein a higher level of at least one epithelial cancer biomarker in the test sample as compared to the level of epithelial cancer biomarker in the control sample is indicative of cancer of epithelial origin, and wherein the epithelial cancer biomarker is selected from the group consisting of Cystatin B, Chaperonin 10, and Profilin. - View Dependent Claims (13, 14, 15, 16, 17, 18)
-
-
4. A method for facilitating the diagnosis of bladder cancer in a patient comprising:
-
a. obtaining a biological sample from the patient; and
b. detecting the presence or absence of Cystatin B in the biological sample, wherein the presence of Cystatin B epithelial cancer biomarker is indicative of bladder cancer.
-
-
5. A method for diagnosing bladder cancer in a patient comprising:
-
a. measuring the levels of Cystatin B present in a biological sample obtained from the patient, a test sample;
b. comparing the level of Cystatin B in the test sample with the level of Cystatin B epithelial cancer biomarker present in a control sample;
wherein a higher level Cystatin B in the test sample as compared to the level of Cystatin B in the control sample is indicative of bladder cancer.
-
-
6. A method for diagnosing invasive bladder cancer in a patient comprising:
-
a. measuring the levels of Cystatin B present in a biological sample obtained from the patient, a test sample;
b. comparing the level of Cystatin B in the test sample with the level of Cystatin B present in a non-invasive control sample;
wherein a higher level Cystatin B in the test sample as compared to the level of Cystatin B in the non-invasive control sample is indicative of invasive bladder cancer.
-
- 19. A kit for detecting at least one epithelial cancer biomarker in a urine sample comprising a container for holding a urine sample, and at least one antibody that specifically binds an epithelial cancer biomarker.
- 21. A kit for detecting Cystatin B in a urine sample comprising a container for holding a urine sample, and at least one antibody that specifically binds Cystatin B.
-
24. A method for assessment of a cancer of epithelial origin, the method comprising:
-
(a) assaying for cystatin B in a sample obtained from a subject; and
(b) determining whether cystatin B is present at a level higher than a predetermined level, thereby indicating whether the subject is at an increased risk of cancer progression. - View Dependent Claims (25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
-
Specification